Search Thermo Fisher Scientific
Talk Title | Speaker | Abstract | Duration |
---|---|---|---|
Genomic Profiling of Myeloid Malignancies in Research and Real-World Clinical Practice | Dr. Than Hein | Over the last decade, rapid advancements in next-generation sequencing (NGS) have enabled researchers to gain deep understanding of the underlying genomic alterations and biological pathways that lead to cancer development and progression. Next-generation sequencing (NGS) is becoming a critical component of molecular testing in both myeloid and lymphoproliferative neoplasms. In this presentation, hear our expert share on the advances in the application of fast NGS for myeloid genomic profiling and how our Ion Torrent Gene Studio System, is able to offer a fully complete end-to-end workflow capable of delivering results in just 1-3 days. | 20 minutes |
The evolving landscape of Measurable Residual Disease (MRD) monitoring and the role of Oncomine Myeloid MRD assays for hematological research | Dr Sophie Rozenzhak | At Thermo Fisher Scientific, our passion drives us to innovate and provide rapid answers to advance the outcomes for patients with hematological malignancies. Next-generation sequencing (NGS) is becoming a critical component of molecular testing in both myeloid and lymphoproliferative neoplasms. It can identify key prognostic markers beyond what is traditionally available with other methods. NGS results upfront was valuable for providing important insights that allowed for better determination of patient prognosis and risk classification. During this presentation, hear about the latest advances in the application of fast NGS for myeloid genomic profiling & myeloid Measurable Residual Disease (MRD) . Hear how rapid NGS is helping to advance research in hemato-oncology care. | 20 minutes |
For Research Use Only. Not for use on diagnostic procedures.
©2023 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries, unless otherwise specified.